Why is Merck KGaA reportedly buying Silence for $1.3 billion?

The reported buyout signals Merck KGaA may be willing to pay for a later-stage RNAi asset with a clear hematology use, rather than wait for more data. Based on the excerpt, the appeal is a Phase 2 blood disorder drug that could challenge a Takeda product and potentially influence RNAi deal valuations in hematology.